Certain anthracycline-containing adjuvant chemotherapy regimens are associated with improved relapse-free survival ( RFS ) and overall survival ( OS ) compared with the classic regimen of cyclophosphamide , methotrexate , and fluorouracil in women with early-stage breast cancer .
